Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding

NCT07345494 is registered in ClinicalTrials.gov with Ascendis Pharma A/S as lead sponsor.

NCT NCT07345494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07345494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Lead sponsor
Ascendis Pharma A/S
Phase
Observational
Overall status
Recruiting
Start date
February 18, 2026
Completion date
January 31, 2036
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypoparathyroidism